When Institutional Ownership Reaches 112 % the Float Is Nearly Exhausted at Vera Therapeutics

Robust buying and call‑heavy options suggest rising conviction amid a tightly held share pool

VERA Vera Therapeutics, Inc.

In this report

01

Institutional Ownership

Quarterly ownership trends, direction, investor count

→

02

Position Flow Analysis

Flow ratio, conviction, new vs closed positions

→

03

Float & Options Context

Put/call ratio, free float estimate, hedging activity

→

04

Insider Trading Patterns

Insider buys/sells, top transactions, cluster buying, post-buy returns

→

05

Smart Money Summary

Convergence/divergence flags, key takeaways

→

Institutional Ownership Trends

Vera Therapeutics, Inc. (VERA) — Ownership Profile

Institutional ownership of Vera Therapeutics has remained exceptionally high at 112.46%, well above the 90% threshold that signals a heavily institutionalized stock and suggests limited free‑float for retail participants. Over the last four quarters the ownership level rose by 13.45 percentage points, but the trend flag is "stable" with only one consecutive quarter of decline, indicating that recent distribution pressure is modest and not yet indicative of a sustained outflow.

Ownership Overview

VERA

The company’s ownership profile reflects strong institutional control, which can provide stability but also compress liquidity for smaller investors. While the latest quarter showed a single‑quarter dip, the overall direction remains neutral rather than a sustained distribution, and the investor base of 238 institutions underscores broad interest despite the high concentration.

Position Flow Analysis

Vera Therapeutics, Inc. (VERA) — Position Flows

Vera Therapeutics, Inc. (VERA) exhibits a strong net accumulation signal, as indicated by its current flow ratio of 1.88, which exceeds the 1.5 threshold for robust buying pressure. The conviction ratio of 0.68 further suggests that existing shareholders are increasing their stakes, reinforcing the positive sentiment from new inflows. Together, these metrics point to both fresh institutional entry and additional commitment from current holders, supported by a net flow figure of 87 indicating sizable aggregate purchases over the recent period.

Position Flow Metrics

VERA

The flow ratio of 1.88 signals that institutions are actively opening new positions in Vera Therapeutics, while the conviction ratio of 0.68 confirms that existing investors are also adding to their holdings. This dual‑sided buying pressure suggests confidence in the company's near‑term catalysts and reduces the likelihood of short‑term distribution risk.

Float & Options Context

Vera Therapeutics, Inc. (VERA) — Float & Options

Vera Therapeutics, Inc. (VERA) exhibits an extremely constrained free float estimated at -12.46%, derived from institutional ownership of 112.46%. A negative float estimate implies that institutions collectively hold more shares than the total outstanding, leaving virtually no publicly tradable shares and raising the potential for short‑squeeze dynamics or limited liquidity. The put/call ratio stands at 0.08, far below the 0.5 call‑heavy threshold, indicating that option market participants are overwhelmingly buying calls relative to puts, a signal of strong bullish sentiment or speculative positioning in the near term.

Float & Options Overview

VERA

The combination of an ultra‑low put/call ratio and a negative free float suggests that while option traders are aggressively betting on upside price movement, the scarcity of tradable shares could amplify price volatility and limit orderly trading. Institutional dominance may constrain supply, increasing the risk of sharp moves if demand spikes or if any large holder decides to sell. Investors should monitor liquidity metrics and any changes in institutional holdings, as divergences between bullish options activity and float constraints could heighten short‑term risk.

Float & Options Context

Vera Therapeutics, Inc. (VERA) — Put/Call Ratio

Insider Trading Patterns

Vera Therapeutics, Inc. (VERA) — Insider Activity

Over the past twelve months, insiders of Vera Therapeutics executed 5 purchases totaling $5.53 million and 17 sales amounting to $4.99 million, yielding a modest net buying value ratio of 1.11. While the dollar‑value balance leans slightly positive, the count ratio (0.29) indicates that sales outnumber purchases three‑to‑one in frequency, suggesting that most insider activity has been selling rather than buying.

Insider Activity Summary

VERA

Director Patrick G. Enright accounted for the bulk of buying activity with two large purchases on June 23 2025 totaling $4.37 million, a clear indication of confidence from board leadership. Conversely, CEO Marshall Fordyce sold 16,925 shares on February 23 2026 worth $710,578; while this sale is sizable, it aligns with typical executive diversification and does not alone signal bearish sentiment. The post‑buy success rate of 60% and average 30‑day return of +0.76% fall below the strong‑timing thresholds (>70% success), suggesting that recent insider purchases have not consistently outperformed short‑term market moves.

Insider Trading Patterns

Vera Therapeutics, Inc. (VERA) — Insider Timeline

Smart Money Summary

Vera Therapeutics, Inc. (VERA) — Summary & Implications

Institutional ownership of Vera Therapeutics, Inc. (VERA) stands at an elevated 112.46% of float, reflecting the presence of multiple institutions holding overlapping shares through various funds. Over the last quarter the ownership rose by 13.45 percentage points, and the flow classification registers as strong accumulation with a flow ratio of 1.73, comfortably above the 1.5 threshold that signals net buying pressure from smart money. Insider activity aligns with this narrative: insiders recorded a net buy of 0.08% of shares, yielding an insider buying/selling (B/S) ratio of 1.11, indicating modest but positive insider participation.

Smart Money Dashboard

Key Takeaways

Institutional ownership surged to 112.46%, up 13.45pp, indicating aggressive fund accumulation.
Flow ratio of 1.73 confirms strong net institutional buying, exceeding the 1.5 benchmark for robust accumulation.
Insider buying ratio of 1.11 reflects modest but positive insider confidence, not merely compensation‑driven selling.
Convergence of institutional and insider buying signals a unified endorsement from smart money.
Despite high ownership levels, the float remains adequate, mitigating concerns about liquidity constraints.

VERA

Both institutional investors and insiders are adding to positions in Vera Therapeutics, creating a clear convergence signal that reinforces confidence in the company's near‑term prospects. The substantial rise in institutional ownership combined with insider buying suggests smart money is positioning for potential upside while still leaving sufficient float for liquidity.

VERA

Related Reports

Explore more at Finexus Reports

Report written 2026-06-07 • Finexus

Disclaimer

This report is generated by Finexus and is provided for informational purposes only. It does not constitute investment advice, a recommendation, or an offer or solicitation to buy or sell any security.

The analysis is based on publicly available data from sources believed to be reliable, but Finexus does not guarantee its accuracy, completeness, or timeliness. Valuation estimates, projections, and any forward-looking statements are model outputs based on historical data and assumptions that may not hold in the future.

Past performance is not indicative of future results. Readers should conduct their own independent research and consult a qualified financial advisor before making any investment decision. Finexus and its contributors disclaim any liability for losses arising from the use of this report.

When Institutional Ownership Reaches 112 % the Float Is Nearly Exhausted at Vera Therapeutics

Disclaimer

When Institutional Ownership Reaches 112 % the Float Is Nearly Exhausted at Vera Therapeutics